Pulse Biosciences stock reports 100 patient trial milestone

Pulse Biosciences stock reported a 100-patient milestone in its PRECISE-BTN thyroid nodule study, while PLSE stood at USD 51.98 on Nasdaq on September 23, 2026. The quote was 1.35 percent below the previous close of USD 52.69, giving the company a market capitalization of USD 3.60 billion.

Thyroid study doubles enrollment

According to Business Wire on September 15, 2026, enrollment reached 100 patients across three US clinical sites, compared with an original 50-patient study design. That is a 100 percent increase in the planned enrollment base.

The first enrolled patient completed the final 12-month follow-up visit in August, while the 100th patient also entered the study during August. Preliminary data are planned for presentation at an upcoming medical society conference, with full data expected after all patients complete the 12-month follow-up.

Cash supports clinical execution

Pulse Biosciences had USD 101.6 million in cash and cash equivalents as of June 30, 2026, according to Business Wire. The company also raised USD 46.8 million in net proceeds through an at-the-market program during the second quarter.

A separate filing dated September 15, 2026, gave Pulse Biosciences access to a new at-the-market program of up to USD 85 million through Mizuho Securities USA, as reported by StockTitan. The agreement does not require the company to sell shares, but it creates additional financing capacity for clinical and commercial development.

Stock remains below yearly high

On September 23, 2026, PLSE traded within a 52-week range of USD 12.56 to USD 58.90. The latest price was USD 6.92 below the yearly high, or 11.75 percent lower, leaving the stock near the upper part of its annual range despite the daily decline.

For investors, the study milestone and financing capacity point to two measurable drivers: clinical validation and the cash needed to fund it. The next valuation signal is likely to come from preliminary trial data and progress toward regulatory support for the nPulse Vybrance system.